Roche's ($RHHBY) experimental breast cancer drug T-DM1 hit another study target, prompting analysts to predict regulatory approval during the first half of next year. After showing it can hold off tumor growth better than another treatment regimen, T-DM1 proved to extend the lives of patients with metastatic breast cancer as well. Report